Eli Lilly expects US FDA approval for oral obesity drug in March 2026

Health

Eli Lilly expects US FDA approval for oral obesity drug in March 2026

Thu, Nov 6, 2025 0 Comments

Audio By Carbonatix

(Reuters) -Eli Lilly expects the U.S. Food and Drug Administration to approve its experimental oral obesity drug, orforglipron, by March 2026, its chief executive said on Thursday.

(Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)

Previous Dutch official says he trusts Nexperia chips will reach world in coming days

Next Take-Two delays ‘GTA VI’ for second time to November next year

Salem News Channel | Today

More Health Headlines

Other News to Consider

Follow SRNNews.com

on Facebook

@SRNNews

Subscribe to our Newsletters RSS Feeds

Salem Media, our partners, and affiliates use cookies and similar technologies to enhance your browsing experience, analyze site traffic, personalize site content, and deliver relevant video recommendations. By using this website and continuing to navigate, you consent to our use of such technologies and the sharing of video viewing activity with third-party partners in accordance with the Video Privacy Protection Act and other privacy laws. Privacy Policy

X CLOSE

Email to a Friend

Eli Lilly expects US FDA approval for oral obesity drug in March 2026

(Reuters) -Eli Lilly expects the U.S. Food and Drug Administration to approve its experimental oral obesity drug, orforglipron, by March 2026, its chief executive said on Thursday. (Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)

X close